

**In the Claims:**

Applicants request amendment of claims 1, 3, 4, 7, 10, 28, and 29, and addition of new claims 32 and 33 as indicated herein. Please cancel claims 9 and 26 without prejudice. A complete list of the claims according to 37 C.F.R. § 1.121(c) follows:

1. (Currently Amended) An isolated mammalian nucleic acid molecule selected from the group consisting of:

(a) ~~Nucleic~~ nucleic acid molecules encoding T128 polypeptide of SEQ ID NO: 1, or a polypeptide with at least 80% identical 90% sequence identity to T128 polypeptide of SEQ ID NO: 1, ~~or a fragment thereof, which is capable of cross reacting with sera from patients with prostate cancer.~~

(b) ~~Nucleic~~ nucleic acid molecules comprising the nucleotide sequence depicted between nucleic acid residues 642 and 1688 of SEQ ID NO: 2. ~~NO: 2.~~

(c) ~~Nucleic~~ nucleic acid molecules, the complementary strand of which ~~specifically hybridises~~ hybridizes under conditions of high stringency to a nucleic acid molecule in (a) ~~or (b).~~ or (b), and

(d) ~~Nucleic~~ nucleic acid molecules with at least 95% sequence identity to a nucleic acid molecule in (a) or (b). ~~the sequence of which differs from the sequence of the nucleic acid molecule of (C) due to the degeneracy of the genetic code.~~

2. (Previously Presented) An isolated nucleic acid molecule according to claim 1, encoding the polypeptide sequence of SEQ ID NO: 1.

3. (Currently Amended) An isolated nucleic acid molecule according to ~~which is at least 80% homologous to a nucleic acid sequence as defined in claim 1~~ which encodes a polypeptide which is expressed in higher concentrations in cancerous tissue compared to that tissue when in a normal state.

4. (Currently Amended) An isolated nucleic acid molecule comprising at least 15 consecutive nucleic acids capable of ~~specifically hybridising~~ hybridizing under conditions of high stringency to a sequence within a nucleic acid molecule according to claim 1.

5. (Previously Presented) A vector comprising a nucleic acid molecule according to claim 1.
6. (Previously Presented) A host cell comprising a vector according to claim 5.
7. (Previously Presented) An isolated protein comprising an amino acid sequence encoded by a nucleic acid molecule according to claim 1.
8. (Previously Presented) An isolated protein according to claim 7 which comprises the amino acid sequence of SEQ ID NO: 1.
9. (Canceled)
10. (Currently Amended) ~~A monoclonal~~ An antibody capable of specifically binding to a polypeptide, or a fragment or derivative thereof, according to claim 7.
- 11.-12. Canceled
13. (Previously Presented) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising the sequence according to claim 1 in a sample from a patient.
14. (Previously Presented) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising the sequence according to claim 1 in combination with a reverse transcription polymerase chain reaction (RT-PCR).
15. (Previously Presented) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a polypeptide according to claim 7.

16. (Previously Presented) The method according to claim 15 wherein the detecting or monitoring step includes a monoclonal antibody selective for the protein or peptide thereof, said antibody capable of detecting the protein or peptide.

17. (Previously Presented) The method according to claim 16 wherein the detecting or monitoring step includes an Enzyme-linked ImmunoSorbant Assay (ELISA).

18. (Previously Presented) The method according to claim 13 wherein the cancer is a gastro-intestinal cancer, kidney cancer or a prostate cancer.

19. (Previously Presented) A kit comprising a nucleic acid molecule as defined in claim 1 for use with a method of detecting or monitoring cancer.

20. (Previously Presented) A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of nucleic acid molecule comprising a nucleic acid sequence according to claim 1 or a pharmaceutically effective fragment thereof.

21. (Previously Presented) A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of a nucleic acid molecule hybridisable under high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence according to claim 1 or a pharmaceutically effective fragment thereof.

22. (Previously Presented) A method of prophylaxis or treatment of cancer comprising administering to a patient a pharmaceutically effective amount of a polypeptide as defined in claim 7 or a pharmaceutically effective fragment thereof.

23. (Previously Presented) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a monoclonal antibody according to claim 10.

24. (Previously Presented) The method according to claim 20, wherein the cancer is a gastro-intestinal cancer.

25. (Previously Presented) A vaccine comprising a nucleic acid molecule having a nucleic acid sequence as defined in claim 1 or a pharmaceutically effective fragment thereof and a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Previously Presented) A polypeptide according to claim 7 or a pharmaceutically effective fragment thereof, attached to a carrier protein.

28. (Currently Amended) A kit comprising a reagent for detecting a protein as defined in claim 7 for use with a method of detecting or monitoring cancer.

29. (Currently Amended) A kit comprising ~~a monoclonal~~ an antibody as defined in ~~claim 4~~ claim 10 for use with a method of detecting or monitoring cancer.

30. (Previously Presented) An immunogenic composition comprising a nucleic acid molecule having a nucleic acid sequence as defined in claim 1 or a pharmaceutically effective fragment thereof and a pharmaceutically acceptable carrier.

31. (Previously Presented) An immunogenic composition comprising a polypeptide according to claim 7 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

32. (New) The antibody of claim 10 wherein the antibody is monoclonal.

33. (New) The antibody of claim 10 wherein the antibody is polyclonal.